Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

September 26, 2015

In the studies presented today, the mechanism of action of IMO-3100, which is inhibition of TLR7- and TLR9-mediated immune responses, was evaluated in non-human primates. IMO-3100 was administered to cynomolgus monkeys by subcutaneous injection. Blood samples were taken prior to IMO-3100 administration and at 24-hour intervals through 96 hours after dosing and at one week after dosing, using blood collection sites remote from the injection site. Peripheral blood mononuclear cells (PBMCs) were isolated from the blood samples and cultured in the presence of TLR7 or TLR9 agonists. Cytokines and chemokines in supernatants from the cell cultures were measured by multiplex assay. Cytokine and chemokine induction in PBMC cultures was compared between samples collected prior to and after IMO-3100 dose administration. Results demonstrated that IMO-3100 inhibited induction of cytokines and chemokines, including TNF-?, IFN-?, IP-10, and IL-6. This inhibition was dependent on both the dosage of IMO-3100 administered and the time after administration of IMO-3100. IMO-3100 inhibition was specific to TLR7 and TLR9, with no significant reduction in cytokine levels inducted in PBMCs cultured with TLR4 or TLR8 agonists.

SOURCE Idera Pharmaceuticals, Inc.